Relationship Between Levels of Advanced Glycation End Products and Their Soluble Receptor and Adverse Outcomes in Adults With Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study explored whether activation of the receptor for advanced glycation end products (RAGE) is implicated in the development of diabetes complications. RESEARCH DESIGN AND METHODS: A case-cohort study was performed in 3,763 participants with prevalent diabetes in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. The hazard ratios (HRs) for death, major cardiovascular events, and new or worsening nephropathy were derived using Cox regression models, and the ability of sRAGE and AGE levels to reclassify the risk of nephropathy was assessed. RESULTS: After adjustment for a range of possible confounders and other risk factors, sRAGE levels were associated with all-cause mortality (HR 1.11 for a 1-SD increase of log sRAGE [95% CI 1.00–1.22]; P = 0.045) and new or worsening nephropathy (HR 1.20 for a 1-SD increase of log sRAGE [95% CI 1.02–1.41]; P = 0.032). Circulating AGE levels were also independently associated with new or worsening nephropathy (HR 1.21 for a 1-SD increase [95% CI 1.08–1.36]; P = 0.001). Both markers also significantly improved the accuracy with which the 5-year risk of new or worsening nephropathy could be predicted (net reclassification index in continuous model, 0.25 for sRAGE and 0.24 for AGE levels). CONCLUSIONS: In adults with type 2 diabetes, increased levels of sRAGE are independently associated with new or worsening kidney disease and mortality over the next 5 years. Higher levels of AGE are also associated with an increased risk of adverse renal outcomes. The AGE/RAGE axis may be of importance in the prevention and management of diabetes complications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Mechanisms of Diabetic Complications
Forbes, J. M., & Cooper, M. E. (2013) · Physiological Reviews · doi:10.1152/physrev.00045.2011 · Cited by 2,890 · cited 1×
“Similarly, the potential importance of AGEs as downstream mediators of renal damage has been demonstrated in studies using chemically disparate inhibitors of AGE formation to retard the development of diabetic kidney disease (31).”
BackgroundSelf-citationAdvanced glycation end-products: A review
Singh, R., Barden, A., Mori, T., & Beilin, L. (2001) · Diabetologia · doi:10.1007/s001250051591 · Cited by 2,597 · cited 1×
“Posttranslational modification of functional groups on vulnerable proteins, lipids, and DNA targets has the potential to alter their structure, stability, and/or function (6,7).”
BackgroundAdvanced Glycation End Products: Sparking the Development of Diabetic Vascular Injury
Goldin, A., Beckman, J. A., Schmidt, A. M., & Creager, M. A. (2006) · Circulation · doi:10.1161/circulationaha.106.621854 · Cited by 2,261 · cited 2×
“The expression of RAGE is increased at sites of vascular injury, including in the diabetic kidney (4).”
BackgroundSoro-Paavonen, A., Watson, A. M. D., Li, J., Paavonen, K., Koitka, A., Calkin, A. C., Barit, D., Coughlan, M. T., Drew, B. G., Lancaster, G. I., et al. (2008) · Diabetes · doi:10.2337/db07-1808 · Cited by 407 · cited 2×
“Genetic depletion of RAGE is able to attenuate complications associated with diabetes (30), and treatment with truncated RAGE also significantly reduces the renal damage in diabetic mice (25).”
BackgroundSelf-citationChalmers, J., & Cooper, M. E. (2008) · New England Journal of Medicine · doi:10.1056/nejme0807625 · Cited by 263 · cited 2×
“This may be because of the long-lasting (legacy) effects of poor glycemic control over many years (1).”
BackgroundSelf-citation
Cited by
New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain
Feldman, E. L., Nave, K.-A., Jensen, T. S., & Bennett, D. L. H. (2017) · Neuron · doi:10.1016/j.neuron.2017.02.005 · Cited by 915
Kidney, heart and brain: three organs targeted by ageing and glycation
Frimat, M., Daroux, M., Litke, R., Nevière, R., Tessier, F. J., & Boulanger, E. (2017) · Clinical Science · doi:10.1042/cs20160823 · Cited by 88
Guerin-Dubourg, A., Cournot, M., Planesse, C., Debussche, X., Meilhac, O., Rondeau, P., & Bourdon, E. (2017) · BioMed Research International · doi:10.1155/2017/7989180 · Cited by 52
“receptor for advanced glycation end-products (RAGE) by AGE is implicated in the development of diabetes complications [31].”
BackgroundFarhan, S. S., & Hussain, S. A. (2019) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2019.06.019 · Cited by 26
Metadata
- Authors
- Thomas, M. C., Woodward, M., Neal, B., Li, Q., Pickering, R., Marre, M., Williams, B., Perkovic, V., Cooper, M. E., Zoungas, S., Chalmers, J., & Hillis, G. S.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-08-07
- Volume
- 38
- Issue
- 10
- Pages
- 1891-1897
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1593781427
- Cited by
- 87
- References
- 7
- FWCI
- 4.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.